KMT2A, previously known as mixed-lineage leukemia (MLL), plays a critical role in hematopoiesis, and its rearrangements implicated in approximately 3–6% of adult de novo AML and up to 10% of therapy-related AML cases [4]. Here, KMT2A is linked to acute myeloid leukemia.